Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains.
The use of substances that could activate the defective chloride channels of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) has been suggested as possible therapy for cystic fibrosis. Using epithelia formed by cells stably transfected with wildtype or mutant (G551D, G1349D) CFTR, we estimated the apparent dissociation constant, K(D), of a series of CFTR activators by measuring the increase in the apical membrane current. Modification of apparent K(D) of CFTR activators by mutations of the nucleotide-binding domains (NBDs) suggests that the binding site might be in these regions. The human NBD structure was predicted by homology with murine NBD1. An NBD1-NBD2 complex was constructed by overlying monomers to a bacterial ABC transporter NBD dimer in the "head-to-tail" conformation. Binding sites for CFTR activators were predicted by molecular docking. Comparison of theoretical binding free energy estimated in the model to free energy estimated from the apparent dissociation constants, K(D), resulted in a remarkably good correlation coefficient for one of the putative binding sites, located in the interface between NBD1 and NBD2.
Moran
O
O
Istituto di Biofisica, CNR, Via DeMarini 6, 16149 Genoa, Italy. moran@ge.ibf.cnr.it
Galietta
L J V
LJ
Zegarra-Moran
O
O
D018528:ATP-Binding Cassette Transporters / Q000819:agonists / Q000235:genetics / Q000502:physiology; D000227:Adenine Nucleotides / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D003550:Cystic Fibrosis / Q000188:drug therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000819:agonists* / Q000737:chemistry / Q000235:genetics*; D019281:Dimerization; D004553:Electric Conductivity; D004594:Electrophysiology; D019833:Genistein / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D017434:Protein Structure, Tertiary; D051381:Rats; D016415:Sequence Alignment; D013816:Thermodynamics
D018528:ATP-Binding Cassette Transporters; D000227:Adenine Nucleotides; C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D019833:Genistein
Clin Sci (Lond). 2003 Feb;104(2):195-201
12546642
J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9
18349064
J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8
16434464
J Neuroendocrinol. 2011 May;23 (5):456-63
21332841
J Clin Endocrinol Metab. 1999 Feb;84(2):743-50
10022447
Biol Reprod. 2008 Mar;78(3):432-7
18003947
BJU Int. 2016 Aug;118(2):221-9
26074405
J Urol. 1995 Jul;154(1):100-4
7539852
Eur Urol. 2014 Dec;66(6):1101-8
24440304
Br J Pharmacol. 2008 Feb;153(4):693-709
18157169
J Endocrinol. 2013 May 07;217(3):R47-71
23549841
J Gerontol A Biol Sci Med Sci. 2003 Dec;58(12):M1103-10
14684707
Circulation. 2004 Nov 9;110(19):3100-7
15520315
Eur Urol. 2012 Jun;61(6):1119-28
22336376
Eur Urol. 2014 Mar;65(3):565-73
24210090
J Clin Oncol. 2010 Jul 20;28(21):3448-56
20567006
Sci Rep. 2016 May 18;6:26220
27189011
Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51
23092636
Circulation. 2005 Sep 20;112(12):1701-10
16157773
Eur Urol. 2014 Apr;65(4):704-9
23433805
Cancer. 2007 Oct 1;110(7):1493-500
17657815
Pharmacol Res. 2004 Sep;50(3):253-9
15225667
Cancer. 2009 Jun 1;115(11):2388-99
19399748
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
17925537
Clin Genitourin Cancer. 2014 Dec;12(6):399-407
25193364
Clin Adv Hematol Oncol. 2006 Sep;4(9):687-96
17099626
J Am Coll Cardiol. 2003 Oct 1;42(7):1306-13
14522500
JAMA. 2011 Dec 7;306(21):2359-66
22147380
Lancet Oncol. 2010 Nov;11(11):1066-73
20933466
Oncology. 2012;82(1):56-8
22310055
Urol Oncol. 2015 Nov;33(11):464-75
26141678
J Clin Oncol. 2009 Jul 20;27(21):3452-8
19506162
J Clin Oncol. 2009 Jan 1;27(1):92-9
19047297
J Am Heart Assoc. 2013 Jul 10;2(4):e000271
23842280
Circulation. 2002 Oct 15;106(16):2132-6
12379585
BJU Int. 2014 Dec;114(6b):E82-E89
24612110
Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7
12207878
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
11836291
Int J Cancer. 2008 Oct 15;123(8):1929-34
18688863
Am J Physiol Heart Circ Physiol. 2006 May;290(5):H2043-50
16361364
Urology. 2008 Feb;71(2):318-22
18308111
Circulation. 2001 Mar 13;103(10):1382-5
11245640
J Clin Oncol. 2006 Sep 20;24(27):4448-56
16983113
Cancer. 2008 May 15;112(10):2188-94
18348297
Cardiovasc Res. 2005 Jan 1;65(1):148-57
15621042
J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23
23210129
J Androl. 2009 Jan-Feb;30(1):23-32
18772488
Endocrinology. 2010 Nov;151(11):5428-37
20861231
J Endocrinol Invest. 2012 Mar;35(3):332-9
22391014
N Engl J Med. 2010 Oct 21;363(17):1621-30
20961245
J Neuroendocrinol. 2009 Mar;21(4):282-92
19187469